

Leukaemia & Lymphoma NI

Report and Financial Statements

Year ended 31 July 2019

Leukaemia & Lymphoma NI

<i>Contents</i>	<i>Page</i>
Legal and administrative information	1
Trustees' report	2
Statement of trustees' responsibilities	11
Independent auditors' report	12
Statement of financial activities	14
Statement of financial position	15
Statement of cash flows	16
Notes on and forming part of the financial statements	17

Leukaemia & Lymphoma NI

Legal and administrative information

Trustees	Trustee Trustee Trustee Trustee Trustee	Mr Richard Buchanan (Chairperson) Mr Bill Pollock Mrs Barbara McClatchey Mrs Shirley Sinclair Mr David Montgomery
Non-trustee office bearers	Patron Secretary Treasurer Public Relations Officer	Professor Jim Dornan Mrs Hazel Black Ms Heather McComb Mrs Frances Parker
Auditors	Hill Vellacott Chartered Accountants Chamber of Commerce House 22 Great Victoria Street Belfast	
Bankers	Ulster Bank Limited City Branch Donegall Square East Belfast	
Solicitors	Edwards & Co 28 Hill Street Belfast	
Principal office	Centre for Cancer Research and Cell Biology Belfast City Hospital 97 Lisburn Road Belfast	
HMRC reference	XN048014	

Leukaemia & Lymphoma NI

Trustees' report

The trustees have pleasure in submitting their annual report together with the audited financial statements of LLNI for the year ended 31 July 2019.

The trustees have adopted the provisions of the Charities SORP (FRS 102) in preparing their annual report and financial statements of the charity.

Legal and administrative information on page 1 forms part of this report.

Objectives and activities

Leukaemia & Lymphoma NI is an unincorporated Members Association governed by its Constitution, amended and updated 19 June 2013. Its objects are to promote research into the causes and cure of leukaemia, lymphoma and other associated blood cancers in Northern Ireland.

History of LLNI

Leukaemia & Lymphoma NI (previously Northern Ireland Leukaemia Research Fund) was established in 1964 by the parents of a teenage girl who died of leukaemia. It is supported throughout the province especially by relatives and friends of patients affected by these diseases. Over the last 55 years they have raised approximately £14 million.

Leukaemia & Lymphoma NI (LLNI) invites applications from scientists and doctors for grants to investigate some particular aspects of the diseases. LLNI has awarded grants to universities, particularly to Queen's University, Belfast, to establish a Chair of Haematology, to carry out fundamental research on the mechanisms involved in blood formation and the development of leukaemia, lymphoma, myeloma and other associated blood cancers.

All grant applications to LLNI are reviewed by a Medical Advisory Committee, chaired and supported by local and national haematology experts. Grant applications are subjected to rigorous scrutiny in accordance with the guidelines laid down by the Association of Medical Research Charities of which LLNI is a member.

Chairman's Report

The summer student programme continued to be popular with Rebecca Johnston and Rebecca Briggs returning to undertake honours projects with Dr Lisa Crawford and Professor Ken Mills respectively.

The charity remains absolutely focussed on raising money to spend on scientific research with the aim of improving survival rates and quality of life for blood cancer patients. And we do this by supporting clinicians, scientists and students researching these cancers in Northern Ireland. This takes place under the guidance of the trustees, who make up our committee of which I am chair. We meet every six weeks or so to review all areas of business, with particular focus on finance, fundraising, progress with the science and an overview of the governance of the charity. We have put extra effort this year into ensuring that we are complying fully with relevant legislation, and guidance from the Charity Commission for Northern Ireland. Our new trustee Brigid Napier, a well known local lawyer, has been particularly helpful to us in this area. As part of this drive to ensure the best possible governance, I am attending a series of training courses specifically aimed at chairs and CEOs of local charities.

As you would expect, the committee often has to take decisions on funding for particular areas of research or posts, and this can be difficult for those of us who don't have scientific backgrounds. So, we rely heavily on our Medical Advisory sub-committee, chaired by Professor Terry Lappin. When requests for funding are received, we ask this sub-committee to give a view on the value of the research, relative to other possible projects. We also consider carefully whether there are other options for funding, in full or in part, and look at options for leveraging funds from elsewhere by making a commitment to a percentage of the total cost of a project. As a committee we are working to improve our scientific knowledge, with regular updates from the scientists to our committee meetings.

We remain a highly efficient charity, with close to 90% of all money raised being spent directly on the science. You will struggle to find another charity of a similar size with such an impressive record of ensuring the money many of you raise is having maximum impact, whilst ensuring the charity is well run. Of course to ensure this remains the case, we rely heavily on Joanne Badger who in effect runs the charity day to day, and on Claire Gilmore (currently on Maternity Leave) and Collette McMorrow who has taken her place for the year. All do an outstanding job both in the office, on LLNI's social media, and in person around the country at events and with supporters. As you know, our office is based right here in this building and we are very grateful to Queens University and the head of the CCRCB Professor Chris Scott in facilitating this. It makes a real difference to us to be able to meet donors here and let them see the research taking place literally just the other side of a glass partition. And this co-location in turn helps us raise money for research here, so the benefit is mutual.

I mentioned last year our then recent agreement to provide nearly £800,000 over five years via the Queen's Foundation to fund various posts here in the CCRCB. Progress with this remains on track, with a lecturer in haematology now in place (Lisa), along with PhD students working to her, and recruitment of a clinical research fellow due soon. The Queen's Foundation sees this package as highly significant, and we aim to build on this funding over the coming years, all of which is helping put Belfast on the map as a key centre for blood cancer research.

We have seen a wider range than ever of fundraising events across Northern Ireland and beyond. The September 2018 Blood Cancer Awareness month saw our Empty Chairs campaign in the media, and this proved to be highly successful in building awareness of the charity, which then translates into income.

This campaign recently won a Chartered Institute of Public Relations award, which was brilliant both for the charity and for ASG the agency that we work with. Also at this time, Glentoran Football Club chose us as their charity of the year, which led to some great publicity, and income. I must mention one of our overseas fundraisers; David Henderson originally from Bangor held a charity big game fishing tournament in the Bahamas for us, raising close to US\$100,000, and he is doing the same again this month. Then in November we had 50 BT staff continuing their outstanding support for their colleague Tim Page by doing a Park Run on a particularly cold morning. Just after Christmas, the Giffin family did their 30th annual Portrush Walk in memory of their daughter Lynda, bringing the total raised over 30 years to close to £200,000. Into January, and we saw the launch of the 'My lasting impression' campaign, with portraits of six volunteers who have had to live with blood cancer. This campaign continues with the portraits now on tour around various shopping centres. In February, Barry Williamson hosted 360 guests at Corrick House near Augher for a brilliant fund raising evening, and thank you for the many people who have helped him raise over £100,000 so far. In May the NI Institute of Hospitality made us their charity of the year, with a fantastic event at the Titanic Centre.

We've had sponsored walks in Bangor, Derry and Strabane, climbs up Croagh Patrick and Slieve Donard, the Four Peaks challenge across Ireland, Clogher Valley and Dromore cycle rides, NIE cycle rides around NI, and Stephen and Ciaran canoeing through the Fermanagh lakes. Team JoJo, the family and friends of Joanne McCawley have done a whole series of events, and Leanne Cascone keeps on running for us. Iris Tweed from Whitehead keeps on selling plants and honey for us, raising a huge sum of money over the years. A Skydive by Laura, Judith, Cilla and Alisdair, a tractor run in Donaghadee, and so many more. Thank you to all have raised money for the charity. You are all brilliant. There have been lots in the past three months too, but I must save them for the next reporting period.

Our branches in East Antrim, Strabane, Belfast and Bangor have continued to do a fantastic job of raising money and awareness in their areas, and I'm really grateful for their continued efforts. Many of their members have been raising money for the charity for decades, doing events year after year, which I know takes a lot of time and effort on the part of many. So thank you.

I have been to many of these events, and participated in some. I don't personally need any reminding of the awfulness of blood cancer, but I am always struck by the huge impact it has on people, whether those who have lost a loved one or those who know someone who has survived. I am also struck by the generosity of so many who want to do something to make a difference, and run some sort of fundraiser for LLNI. I've met many amazing, inspirational and brave people over the year, who are often struggling to deal with their loss, or finding living with cancer so very hard and my heart goes out to them. This is what keeps us doing what we do, to try to stop this terrible impact on lives for the future. So, thank you for your continued support. Thank you for helping to make last year such a success, and please stay with us as we build on this for the year ahead. Our mission remains clear; with your help, we're making blood cancer history.

Review of branch activities and developments

Leukaemia & Lymphoma NI had 3 branches in the province during the year as follows:

- Bangor
- East Antrim
- Strabane

Each branch conducts its own fund raising activities which include such activities as street collections, craft fairs and sponsored walks.

Funds are also generated through donations, many in memory of someone who has died from a blood cancer, or from families where someone has been diagnosed with a blood cancer. Other sources include interested individuals, organisations and legacies.

A Medical Advisory Committee is responsible for recommending to LLNI's Central Committee suitable research programmes.

Leukaemia & Lymphoma NI

Based upon the advice of the Medical Advisory Committee of LLNI financial support is provided to the Haematology Research Group (HRG) at Queen's University Belfast. LLNI supports the laboratory work of two Principal Investigators who lead small groups of researchers working on various haematological disease.

Professor Ken Mills

Professor Ken Mills is Chair of Experimental Haematology within the blood cancer research group. His research is focused on Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS) using high density micro arrays, miRNA and epigenetic profiling. These assays involve the simultaneous analysis of large numbers of RNA or miRNAs targets with the aim of disease classification, improving prognostic markers and identifying and screening novel therapies.

Professor Mills is Chair of EU COST Action entitled "European Genomic and Epigenetic Study on MDS and AML", a consortium of laboratories in 22 EU countries. He is also lead for the Belfast Experimental Cancer Medicine Centre (ECMC), Head of the Experimental Cancer Medicine Research Division in the CCRCB and Academic Lead for the Core Technology Units in the School of Medicine. Professor Mills is a member of the Executive Committees of the Northern Ireland Cancer Registry and Northern Ireland Cancer Trials Centre. Professor Mills sits on the Scientific Review Committee of the Northern Ireland BioBank and the Northern Ireland Cohort Study for the Longitudinal Study of Ageing (NICOLA). He is a regional committee member of the Royal College of Pathologists and an Examiner for the Clinical Scientist programme.

Leukaemia & Lymphoma NI have awarded Professor Mills and infrastructure grant which has been used to fund travel to research workshops, conferences and meetings, small items of equipment and contributes to consumables for all projects within the HRG.

Medical and Scientific Advisory Committee Report – Professor Ken Mills

I would like to begin this report by thanking Leukaemia & Lymphoma NI for their continued support for the Blood Cancer Research Group with the Centre for Cancer Research and Cell Biology (CCRCB) based in Queen's University Belfast.

Without their support and funding across the spectrum of blood cancers, we could not undertake the research to understand these diseases and develop novel therapies. Blood cancer is an umbrella term for around 130 different diseases – none of which have the word cancer in their name. Some of the diseases also have some of poorest outcomes in terms of survival and our research aims to change that.

It is pleasing to note the new strategy for the CCRCB has highlighted that Blood Cancer is one of the four pillars for the centres research focus. That highlights the quality of the research being undertaken but also recognizes the value of the support from the LLNI.

As announced last year, the LLNI had invested around £800,000, via Queen's Foundation (QF), to fund a new lectureship in blood cancer and we were very pleased that one of our own post-docs was awarded the post and started in January 2019. Dr Lisa Crawford has a strong record of research into myeloma and has established collaborations with colleagues in Sheffield, England and Boston, USA. She has already made an impact in the research group and has contributed to teaching and other activities in the School.

Other parts of the QF package included supporting a Clinical Research Fellowship from August 2019 and this was advertised recently and interviews for this will take place in mid-December 2019.

In recognition of Dr Crawford's recent appointment, the LLNI also agreed to fund a PhD studentship from October 2019 and Jonathan Morgan was appointed, Jonathan has previously undertaken his Master's project with Dr Crawford. Dr Crawford was also awarded a Department of Education (DfE) studentship, the DfE research only come with an annual budget of £700; however, this will be supplemented by LLNI funding and so we can rightfully claim that Roisin McAvera as one of the merry band of PhD students funded by the LLNI! Jonathan and Roisin will join our existing students; Clare Crean and Harmony Black. As part of our global reach, I am pleased that Maryam Al Barashdi joined us in October with a scholarship from the Government of Oman.

The Blood Cancer Research Group also welcomed Dr David Campbell, a post-doctoral fellow who is funded by Bloodwise, and we were pleased to get another Little Princess Trust grant to continue funding Dr Katrina Lappin whilst Dr Ana Gonzales-Sanchez is now the only LLNI funded post-doc.

During the year, several of the LLNI group left. Dr Cliona Johnston, one of the Golden Anniversary PhD students, graduated and is now working for Randox. Whilst the other student funded on the Golden Anniversary programme, Dr James Smith also completed his PhD and obtained a post-doctoral research post at University College Dublin where he is researching paediatric AML. One further departure, Dr Kyle Matchett, who has been funded by the LLNI for several years, was appointed as Lecturer in Molecular Immunology in Ulster University. As an update, Dr Suzanne McPherson who undertook a clinical research fellowship in the group in 2015-2018 has been appointed as consultant haematologist in Antrim. We wish Suzanne, Cliona, James and Kyle well in their future careers.

In the clinical research environment, Dr Bridgin Merron, who is a Consultant in Antrim, returned from Southampton University after a fellowship, part funded by the LLNI, to develop skills in early phase trials for blood cancer, specifically lymphoma. It is hoped that Dr Alistair Foy, Belfast HSCT, will be able to visit King's College Hospital in London, in the New Year, to develop his understanding of MDS. These activities will ensure that Northern Ireland will benefit from their expertise gained by working with leaders in these fields. Nearer home, the LLNI funded clinical research nurse, Ruth Irwin has retired, and we wish her well, and Tracey McGuigan has been appointed as her replacement and we look forward to working with her across several projects.

We continue to publish our research and although the numbers are slightly down on the previous year, which was one of the best years ever, we are moving forward and have several in advance stages of preparation and out for review at the moment. Our work has been presented at workshops, invited seminars and international meetings such as the American Society for Hematology in Atlanta, the European Haematology Association in Stockholm, the Haematology Association of Ireland in Cork and the Euroclonality meetings in Rotterdam and Kiel. Dr Crawford was invited to present at the UK Myeloma forum on the back of her presentation at ASH2018 and with Clare and Katrina, has had posters accepted for ASH2019 in December.

As mentioned earlier, we were pleased to gain a second grant from the Little Princess Trust / Children's Cancer Leukaemia Group based on work initiated under previous LLNI grants. This was the second grant we obtained from them in a year and as a result we also hosted the Childhood Leukaemia Research Annual Forum in September, which was the first time it was held in Northern Ireland and turned out to have the largest attendance ever! We are pleased that we have finally had our Associate Membership of the EU funded IMI2 project approved, HARMONY is a €40M five-year project to develop the use of Big Data for improving outcomes in blood cancers. Belfast will be actively contributing to studies in AML, MDS and CLL.

We have had several overseas visiting students, Rubin Grosso joined us from 3 months from Argentina to complete part of his PhD studies, whilst Julie Alcocer from Lyon in France spent 5 months here was joined by Gabrielle Feydel and Astrid Bouchet-Mathiou, both from Clermont in France. At the moment, Amber de Lange from the Netherlands will be with us from September to January 2019. Other summer students included Charlotte McDonald who has returned to undertake her honours projects with Dr Lisa Crawford. One of last year's undergraduate students, Claudia Hamilton, was also awarded the LLNI undergraduate prize for the highest score in the Blood Cancer in her final year.

We shouldn't forget the on-going contribution of Anne Jordan, funded by LLNI from many years, to undertake assessment of stem cell harvest quality for blood cancer patients and who processes the diagnostic samples for in the Northern Ireland Biobank contributing to the around 900 samples now in the bank. Anne has also been undertaking preliminary research on the use of snake venom for the treatment of AML and this has now involved another honours project student, Natalie Clendenning, who is working in collaboration with Ulster University. Two other project students, Deirdra Venney and Katie Carson are working with Drs Katrina Lappin and Ana Gonzales-Sanchez, on validating some candidate drugs identified from our repurposing screens. Whilst we also have two Masters students with the group, Fionnula Mooney working on mutations in CLL with Dr Mark Catherwood and Lilia Cabrera working on epigenetic therapies with Dr. Adone Mohd-Sarip.

As ever, I want to thank the members of the Blood Cancer research group; not only for their contributions to the research but also always being "willing" to be photographed, videoed, interviewed, posted on social media or talking to patients, families, the public and fundraisers to maintain that vital connection between the science and our dedicated supporters.

Finally, to everybody involved with the Leukaemia & Lymphoma NI – thank you. Thank you to the branches and supporters spending their evenings and weekends raising money to enable use to undertake our research. Thank you for the “behind-the-scenes” team of Claire Gilmore, Collette McMorrow and Joanne Badger for all their work linking the fund-raising, public awareness, the committee and the research team. Thank you to the LLNI committee for their continued support and believe in the research we are undertaking. In particular, I need to thank Chairman Richard Buchanan and the Past and Current Chairman of the Medical and Scientific Advisory Committee, Professor Curly Morris and Professor Terry Lappin for their support and interest in the research progress.

I know I have said it before, but it is worth repeating, the LLNI is a charity based in Northern Ireland funding research in Northern Ireland which is having a global impact.

Professor Mary Frances McMullin

Professor Mary Frances McMullin is a Professor of Clinical Haematology in Queens University Belfast and Consultant Haematologist to Belfast Health and Social Care Trust. Her research focuses on erythrocytosis, myeloproliferative neoplasms and acute myeloid leukaemia looking at the causes of erythrocytosis and the pathogenesis, epidemiology and treatment modalities in the neoplastic disorders. She has an extensive portfolio of clinical trials in the clinical areas of interest.

Professor McMullin is involved on the management committee of the network of experts in the molecular diagnosis of myeloproliferative neoplasms and related disease MPN&MPNr-EuroNET COST Action BM0902 and is chair of Working Group 3 in this COST action. Professor McMullin was President of the Haematology Association of Ireland (2010-2011). Professor McMullin was Chair of the MPN Sub Group from 2006 -2011 and Chair of the British Committee for Standards in Haematology 2011-2015.

She is a long-term member of the executive committee of the Northern Ireland Cancer Clinical Trials Centre and the Belfast Experimental Cancer Medicine Centre, and an examiner for the Royal College of Pathologists and the Royal College of Physicians in Edinburgh. She is a Fellow of the Academy of Medical Educators and has extensive commitments in Education in Haematology including for the European Haematology Association.

Core Tissue Support

LLNI provides core tissue culture support through an annual grant for laboratory infrastructure support for experiments involving cellular and molecular biological techniques.

Studentships

LLNI continues to fund various PhD students and Post-Doctoral Students. In 2018-2019 it funded 2 PhD students and one Post-Doctoral Students. This funding continues in 2019-2020 with 4 additional PhD students receiving funding.

Summer Studentships

LLNI continues to support five summer studentships in the Centre for Cancer Research and Cell Biology at Queen’s University Belfast. The students contribute to a number of projects being undertaken by the Haematology Research Group.

Financial review

Details of the results for the year are set out in the statement of financial activities on pages 14 and 15 and the related notes.

Leukaemia & Lymphoma NI

Statements of trustees' responsibilities

Investment policy and returns

LLNI's investments are managed by Cunningham Coates Stockbrokers Belfast and were valued at £1,293,843 as at 31 July 2019.

During the past financial year, we have received dividend income from these investments totalling £63,674.

The relationship with Cunningham Coates continues to work well, although we are in the process of re-establishing a personal relationship with the broker dealing with LLNI, after the unexpected departure of his predecessor

Reserves

The Trustees have reviewed the resources of LLNI taking into consideration the variable natures of its income and the need to fulfil the fixed commitment of grant to Queen's University as formalised and confirmed to the University for the period 1 October to 30 September in each year.

Governance and Internal Control

The organisation structure of LLNI is as set out in the Constitution of LLNI at paragraph 10:

"The following officers, all of whom shall be honorary, that is to say a Patron, a President, a Chairperson, one or more Vice Chairpersons, a Secretary, a Treasurer and a Public Relations Officer shall be elected annually in such a manner and shall discharge such duties as LLNI in general meeting shall from time to time determine."

The major risks to which LLNI would be exposed are centred around the following areas:

i. Misuse and misappropriation of funds coupled with poor financial controls.

LLNI's objective is to raise money to finance appropriate research into the causes and possible cures for leukaemia, lymphoma, myeloma and other associated blood cancers. This research is controlled, supervised and vetted by LLNI's Medical Advisory Committee (MAC) under the Chairmanship of Professor T Lappin, assisted by a group of eminent academics. Research projects are carefully scrutinised and "peer reviewed" by the MAC before any recommendations are made within the budgetary confines of LLNI.

The funds to support research are carefully controlled by the Central Committee of LLNI, which received a financial report by the honorary treasurer at each meeting of the Central Committee. The Committee, under the Chairmanship of Mr Richard Buchanan, meets approximately 8 times per year, with all members expected to make every effort to attend every meeting to ensure compliance with Charity Commission guidelines.

ii. Lack of proper public liability insurance to cover fund raising activities by members and the possibility of legal action against members.

Members' fund raising activities are covered for public liability by LLNI's insurance brokers. Members have been circularised that any activity which has the slightest element of risk must have the approval of the insurers before proceeding. High risk activities are not permitted.

Auditors

Hill Vellacott have expressed their willingness to continue in office as auditors and a resolution for their re-appointment will be proposed at the Annual General Meeting.

By order of the board on 14 November 2019

A handwritten signature in black ink, appearing to read 'R. Buchanan', with a long horizontal flourish extending to the right.

Mr Richard Buchanan
Chairman

The constitution of Leukaemia & Lymphoma NI requires the trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of LLNI and of the surplus or deficit of LLNI for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that LLNI will continue in business.

The trustees are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of LLNI and to enable them to ensure that the financial statements comply with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of LLNI and to prevent and detect fraud and other irregularities.

The trustees of the Charity who held office at the date of approval of these financial statements, as set out on page 1, each confirm so far as we are aware that:

- there is no relevant audit information of which the Charity's auditors are unaware; and
- we have taken all the steps that we ought to have taken as trustees in order to make ourselves aware of any relevant audit information and to establish that the Charity's auditors are aware of that information.

By order of the board on 14 November 2019



Mr Richard Buchanan
Chairman

Independent auditors' report to the members of Leukaemia & Lymphoma NI

We have audited the financial statements of Leukaemia & Lymphoma NI for the year ended 31 July 2019 which comprise statement of Statement of Financial Activities, Statement of Financial Position, the Statement of Cash Flows and the related notes. These financial statements have been prepared under the historical cost convention and the accounting policies set out therein.

This report is made solely to LLNI's trustees, as a body, in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. Our audit work has been undertaken so that we might state to LLNI's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than LLNI and LLNI's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

As described in the Statement of Trustees' Responsibilities LLNI's trustees are responsible for the preparation of financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom General Accepted Accounting Practice).

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. We also report to you if, in our opinion, the Trustees' Report is not consistent with the financial statements, if LLNI has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding trustees' remuneration and transactions with LLNI is not disclosed.

We read the Trustees' Report and consider the implications for our report if we become aware of any apparent misstatement within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to LLNI's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion, we also evaluated the overall adequacy of the presentation of information in the financial statements.

Independent auditors' report to the members of Leukaemia & Lymphoma NI
(continued)

Opinion

In our opinion, the financial statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of LLNI's affairs as at 31 July 2019 and of the incoming resources and application of resources for the year then ended. The financial statements have been properly prepared in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987.

In our opinion the information given in the Trustees' Report is consistent with the financial statements.

Hill Vellacott
Statutory Auditor
Chartered Accountants

Leukaemia & Lymphoma NI

Statement of Financial Activities (including Income and Expenditure Account) Year ended 31 July 2019

		Unrestricted funds	Restricted funds	2019 Total	2018 Total
	Note	£	£	£	£
Income and Endowments					
Income from charitable activities					
Donations and gifts	2	293,068		293,068	373,551
Legacies	3	2,111		2,111	6,946
Activities for generating funds	4	284		284	-
Stem cell harvest		12,000		12,000	11,660
Investment income	5	70,174		70,174	84,169
Sundry Income					-
Profit/(loss) on disposal of investments		7,437		7,437	42,269
		<hr/>	<hr/>	<hr/>	<hr/>
Total incoming resources		385,075		385,075	518,595
		<hr/>	<hr/>	<hr/>	<hr/>
Resources expended					
Cost of generating funds					
Fundraising trading: Cost of goods sold and other costs		994		994	4,950
Charitable expenditure					
Grants towards:					
– salaries		353,531		353,531	401,561
– supplies and equipment		155,202		155,202	94,328
– travelling expenses		22,234		22,234	17,637
Charitable activities	7	77,890		77,890	88,097
		<hr/>	<hr/>	<hr/>	<hr/>
Total resources expended		609,851		609,851	606,573
		<hr/>	<hr/>	<hr/>	<hr/>
Net resources expended		(224,776)		(224,776)	(87,978)
Movement on valuation of investments		(58,301)		(58,301)	5,212
		<hr/>	<hr/>	<hr/>	<hr/>
Net movement in funds		(283,077)		(283,077)	(82,766)
Fund balances brought forward		1,689,412		1,689,412	1,772,178
		<hr/>	<hr/>	<hr/>	<hr/>
Fund balance carried forward		1,406,335		1,406,335	1,689,412
		<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

LLNI has no recognised gains or losses other than those included on the preceding page and therefore no separate statement of total recognised gains and losses has been presented.

The incoming resources and resources expended amounts as stated on the preceding page are derived solely from continuing operations.

The notes on pages 17 to 21 form part of these financial statements.

Leukaemia & Lymphoma NI

Statement of Financial Position

31 July 2019

	<i>Note</i>	2019		2018	
		£	£	£	£
Fixed assets					
Intangible fixed assets			790		790
Investments at market value	9		1,293,843		1,548,547
Current assets					
Stock		1,000		1,000	
Prepayments		3,488		1,414	
Cash at bank	10	215,712		233,868	
			<u>220,200</u>	<u>236,282</u>	
Current liabilities					
Accruals		(108,498)		(96,207)	
			<u>111,702</u>	<u>140,075</u>	
Net current assets					
			<u>1,406,335</u>	<u>1,689,412</u>	
Funds					
Unrestricted funds - general funds	12		525,791		668,527
- designated funds			880,544		1,020,885
Restricted funds					-
			<u>1,406,335</u>	<u>1,689,412</u>	

The financial statements were approved by the Trustees on 14 November 2019 and signed on its behalf by:



Mr Richard Buchanan
Chairman

The notes on pages 17 to 21 form part of these financial statements.

Leukaemia & Lymphoma NI

Statement of Cash Flows

31 July 2019

	2019 £	2018 £
Cash flows from charitable activities (loss) / surplus for the financial year	(284,008)	(82,767)
<i>Adjustments for:</i>		
Interest received	(458)	(227)
Movement on valuation of investments	58,508	(5,212)
Gain on disposal of investments	(7,437)	(42,269)
Accrued expenses	12,291	2,668
<i>Changes in:</i>		
Stock	-	-
Prepayments	(2,073)	(325)
Cash generated from charitable activities	(222,247)	(128,132)
Interest received	458	227
Net cash from charitable activities	(221,789)	(127,905)
Cash flows from investing activities		
Purchase of shares	(281,730)	(176,289)
Proceeds from sale of shares	269,096	395,903
Net cash used in investing activities	(234,423)	91,709
Net increase/(decrease) in cash and cash equivalents		
Cash and cash equivalents at beginning of year	487,032	395,322
Cash and cash equivalents at end of year	252,609	487,031
Cash and cash equivalents		
Cash at bank	215,712	233,868
Investment cash accounts	36,897	253,163
	252,609	487,031

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

1 Accounting policies

The accounting policies are consistent with those of the previous year.

(i) Basis of accounting

LLNI prepares its financial statements under historical cost convention, as modified by the inclusion of investments at market value. The financial statements have been prepared in accordance with the Charities SORP (FRS 102).

(ii) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by LLNI for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Designated funds are unrestricted funds that have been set aside by the trustees for particular purposes. Details of the designated funds are described in note 12.

Investment income and gains are allocated to the unrestricted fund.

(iii) Incoming resources

All incoming resources are included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

Due to the nature of donated income, such income is not capable of control by LLNI and branches before receipt. However, financial controls are in place to ensure accurate recording and safeguarding of all income received by LLNI.

Leukaemia & Lymphoma NI

Notes *(continued)*

1 Accounting policies *(continued)*

(iv) Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Grants payable for research are included in the statement of financial activities when approved by the trustees after review by a medical advisory committee. The value of grants unpaid at the year end is accrued.

Management and administration costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

(v) Investments

Investments are stated at market value at the balance sheet date. The statement of financial activities includes the net gains and losses arising on revaluations and disposals throughout the year.

2 Donations and gifts

	Unrestricted £	Restricted £	2019 £	2018 £
Income from general donations	258,786	-	258,786	338,981
Gift Aid	8,135	-	8,135	-
Branches				
Bangor and district	5,214	-	5,214	14,986
East Antrim	20,933	-	20,933	19,584
	<hr/>	<hr/>	<hr/>	<hr/>
	293,068	-	293,068	373,551
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

3 Legacies

	2019 £	2018 £
From the estate of:		
G.A. Stewart	-	6,946
Doris Euston	500	-
Corry Legacy	500	-
A.M. Crawford	111	-
Henrietta Killops	1,000	-
	<hr/>	<hr/>
	2,111	6,946
	<hr/> <hr/>	<hr/> <hr/>

All the legacies are unrestricted.

4 Sale of Goods

Promotional items such as pens, T-shirts, wedding favours, badges and wrist bands are sold on the website leukaemia&lymphomani.org.

5 Investment income

	2019 £	2018 £
Bank interest	458	227
Other interest	6,042	7,921
Dividends	63,674	76,021
	<hr/>	<hr/>
	70,174	84,169
	<hr/> <hr/>	<hr/> <hr/>

6 Staff numbers and costs

LLNI had no employees during the year. LLNI pays grants to Queen's University towards the salaries of employees working on leukaemia research and to cover the salaries of those working on the administration of the charity.

7 Charitable activities

	2019 £	2018 £
Insurance	1,110	1,045
Audit and accountancy	3,940	3,740
Legal	-	1,121
Events management	22,952	24,184
Sundry expenses	279	89
Promotion and advertising	33,565	46,321
Investment management charges	10,843	8,707
Bank fees	310	33
Telephone	461	470
Computer costs	1,326	314
Subscriptions	3,104	2,073
	<hr/>	<hr/>
	77,890	88,097
	<hr/> <hr/>	<hr/> <hr/>

8 Net outgoing resources

Net outgoing resources are stated after charging:

	2019 £	2018 £
Auditors' remuneration	3,940	3,740
	<hr/> <hr/>	<hr/> <hr/>

9 Fixed asset investments

	2019 £	2018 £
At 1 August 2018	1,295,383	1,500,632
Additions at cost	281,730	176,289
Disposal proceeds	(269,303)	(429,019)
Profit on disposal	7,437	42,269
Revaluation	(58,301)	5,212
	<u>1,256,946</u>	<u>1,295,383</u>
Monies held	36,897	253,164
	<u>1,293,843</u>	<u>1,548,547</u>

10 Cash at bank

	2019 £	2018 £
Current account	102,868	132,606
Branch bank accounts	17,278	8,979
Special interest bearing account	92,435	92,274
Petty cash	20	9
Held in PayPal account	3,111	-
	<u>215,712</u>	<u>233,868</u>

11 Branch Donations received and transfers to central account

Branch	Opening bank balance 01/08/18	Net Donations Lodged to Bank £	Expenses £	Amount transferred to central account £	Closing bank balance 31/07/19 £
Bangor	246	5,214	27	5,433	-
East Antrim	8,733	20,933	388	12,000	17,278
	<u>8,979</u>	<u>26,147</u>	<u>415</u>	<u>17,433</u>	<u>17,278</u>

Leukaemia & Lymphoma NI

Notes (continued)

12 Unrestricted funds

	Balance at 1 August 2018	Transfer to / (from) designated funds	Income	Expenses	Balance at 31 July 2019
	£		£	£	£
General reserves	668,527	(390,371)	385,075	(137,440)	525,791
Designated funds					
Stem Cell Harvest	19,413	18,943		(18,943)	19,413
General account for consumables	20,000	30,262		(31,304)	18,958
Core tissue culture support	19,167	23,824		(24,032)	18,959
Grade 4 clerical officer	40,146	15,872		(32,684)	23,334
Haematology	186,673	26,910		(101,916)	111,667
NILRF Coordinator expenses	1,565	68,130		(38,118)	31,577
Mosaic Study	33,333	-		(16,667)	16,666
Golden Anniversary Programmes:					
PhD Studentship	21,994	(21,994)		-	-
Post Doctoral Fellowship	7,167	26,081		(33,248)	-
Post Doctoral Fellowship	8,222	15,927		(24,149)	-
Clinical trials nurse	73,853	12,088		(39,167)	46,774
PhD Studentship	-	26,057		(26,057)	-
PhD Studentship	172,596	(34,876)		(25,958)	111,762
Research Fellow	413,839	-		(75,000)	338,839
Research Studentship	2,917	7,808		(9,125)	1,600
Studentship	-	125,186		(26,344)	98,842
Foy Grant	-	8,000		(8,000)	-
Research Grant	-	16,667		-	16,667
Clerical Officer	-	25,486		-	25,486
	<u>1,689,412</u>	<u>-</u>	<u>385,075</u>	<u>(668,152)</u>	<u>1,406,335</u>

The general reserve fund represents those funds which are unrestricted and not designated for other purposes.

The designated funds have been set aside by LLNI for the department of Haematology, CCRCB, Belfast City Hospital mainly to aid with the administration of research projects.